A first-in-human study of Tenalisib in patients with R/R hematologic malignancies- European study
16369
news-template-default,single,single-news,postid-16369,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

A first-in-human study of Tenalisib in patients with R/R hematologic malignancies- European study

Home > A first-in-human study of Tenalisib in patients with R/R hematologic malignancies- European study

22 Oct A first-in-human study of Tenalisib in patients with R/R hematologic malignancies- European study

Posted at 16:21h in by

Glad to share the publication of the manuscript “A first-in-human study of Tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in patients with relapsed/refractory hematologic malignancies: results from the European study” in Clinical Lymphoma Myeloma and Leukemia

 

No Comments

Post A Comment